drugset / Trial / NCT00423163

A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis

NCT00423163

Phase 4 Withdrawn Astellas Pharma Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the therapeutic effectiveness of voriconazole + micafungin versus voriconazole alone as primary therapy for invasive aspergillosis.

Timeline

Start
2007-02
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Micafungin Peptide
Subject Voriconazole Small molecule